NASDAQ:RSLS ReShape Lifesciences (RSLS) Stock Price, News & Analysis → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Free RSLS Stock Alerts $0.18 +0.00 (+0.56%) (As of 10:53 AM ET) Add Compare Share Share Today's Range$0.17▼$0.1850-Day Range$0.15▼$0.1952-Week Range$0.14▼$2.80Volume167,587 shsAverage Volume726,118 shsMarket Capitalization$2.35 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get ReShape Lifesciences alerts: Email Address ReShape Lifesciences MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside100.0% Downside$0.00 Price TargetShort InterestHealthy2.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.14 out of 5 stars 0.0 Analyst's Opinion Amount of Analyst CoverageReShape Lifesciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.34% of the float of ReShape Lifesciences has been sold short.Short Interest Ratio / Days to CoverReShape Lifesciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ReShape Lifesciences has recently decreased by 33.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldReShape Lifesciences does not currently pay a dividend.Dividend GrowthReShape Lifesciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RSLS. Previous Next 2.2 News and Social Media Coverage News SentimentReShape Lifesciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ReShape Lifesciences this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ReShape Lifesciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of ReShape Lifesciences is held by insiders.Percentage Held by InstitutionsOnly 22.06% of the stock of ReShape Lifesciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioReShape Lifesciences has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWar Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>> About ReShape Lifesciences Stock (NASDAQ:RSLS)ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.Read More RSLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RSLS Stock News HeadlinesApril 16, 2024 | morningstar.comReshape Lifesciences Inc RSLSApril 7, 2024 | seekingalpha.comRSLS ReShape Lifesciences Inc.April 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.April 3, 2024 | msn.comWill GLP-1 medications replace weight loss surgery?April 3, 2024 | finance.yahoo.comReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagApril 2, 2024 | finance.yahoo.comQ4 2023 ReShape Lifesciences Inc Earnings CallApril 1, 2024 | globenewswire.comReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | benzinga.comLatest News for Reshape Lifesciences Stock (NASDAQ:RSLS)April 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.March 28, 2024 | finanznachrichten.deReShape Lifesciences Inc: ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon SystemMarch 28, 2024 | globenewswire.comReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon SystemMarch 4, 2024 | msn.comReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut planMarch 4, 2024 | globenewswire.comReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEXFebruary 29, 2024 | investing.comReShape Lifesciences Inc (RSLS)February 29, 2024 | edition.cnn.comReShape Lifesciences, Inc.February 24, 2024 | thestreet.comReShape Lifesciences Inc.February 22, 2024 | benzinga.comReshape Lifesciences Stock (NASDAQ:RSLS) Insider TradesFebruary 22, 2024 | finance.yahoo.comReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEXFebruary 22, 2024 | finance.yahoo.comReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEXFebruary 22, 2024 | globenewswire.comReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEXJanuary 24, 2024 | finance.yahoo.comReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEXDecember 20, 2023 | marketwatch.comReShape Lifesciences Shares Rise 5.6% on Potential Strategic Merger and Acquisition Partnership AlternativesDecember 13, 2023 | msn.comWhy ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving PremarketDecember 13, 2023 | msn.comWhy ReShape Lifesciences Stock Is Ripping HigherDecember 13, 2023 | investorplace.comWhy Is ReShape Lifesciences (RSLS) Stock Up 68% Today?December 13, 2023 | finanznachrichten.deReShape Lifesciences Inc: ReShape Lifesciences Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band 2.0 FLEXDecember 13, 2023 | msn.comReShape Lifesciences spikes as FDA clears new weight loss optionSee More Headlines Receive RSLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2020Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:RSLS CUSIP29365M20 CIK1371217 Webwww.reshapelifesciences.com Phone(949) 429-6680FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Target$0.00 High Stock Price Target$0.00 Low Stock Price Target$10,000,000.00 Potential Upside/Downside+4,369.3%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,390,000.00 Net Margins-131.22% Pretax Margin-130.62% Return on Equity-187.89% Return on Assets-97.55% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio1.74 Sales & Book Value Annual Sales$8.68 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book0.35Miscellaneous Outstanding Shares13,140,000Free Float13,122,000Market Cap$2.35 million OptionableNot Optionable Beta0.22 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Dan W. Gladney (Age 71)Executive Chair Comp: $129.5kMr. Paul F. Hickey (Age 59)CEO, President & Director Comp: $506.42kMr. Thomas Stankovich (Age 63)Senior VP & CFO Comp: $307.12kDr. Mark B. Knudson Ph.D. (Age 75)Co-Founder and Special Advisor to the CEO Comp: $33kDr. Katherine S. Tweden Ph.D. (Age 63)Co-Founder Comp: $338.41kMr. Al DiazVice President of Operations and R&DDr. Dov Gal D.V.M.M.B.A., VP of Regulatory Clinical Quality & Compliance OfficerJody B. DahlmanDirector of CommunicationsMr. Naqeeb A. Ansari (Age 63)Senior Vice President of Global Commercial Operations Comp: $327.46kMore ExecutivesKey CompetitorsQuoin PharmaceuticalsNASDAQ:QNRXNemaura MedicalNASDAQ:NMRDProSomnusNASDAQ:OSATenon MedicalNASDAQ:TNONDynatronicsNASDAQ:DYNTView All CompetitorsInsidersThomas StankovichSold 131 sharesTotal: $35.37 ($0.27/share)Thomas StankovichSold 39 sharesTotal: $36.27 ($0.93/share)Thomas StankovichSold 118 sharesTotal: $105.02 ($0.89/share)Thomas StankovichSold 39 sharesTotal: $55.38 ($1.42/share)Thomas StankovichSold 108 sharesTotal: $154.44 ($1.43/share)View All Insider Transactions RSLS Stock Analysis - Frequently Asked Questions What is ReShape Lifesciences' stock price target for 2024? 0 analysts have issued twelve-month price objectives for ReShape Lifesciences' stock. Their RSLS share price targets range from $10,000,000.00 to $0.00. On average, they expect the company's share price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%. View analysts price targets for RSLS or view top-rated stocks among Wall Street analysts. How have RSLS shares performed in 2024? ReShape Lifesciences' stock was trading at $0.2497 at the start of the year. Since then, RSLS stock has decreased by 28.3% and is now trading at $0.1790. View the best growth stocks for 2024 here. Are investors shorting ReShape Lifesciences? ReShape Lifesciences saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 487,800 shares, a decrease of 33.1% from the March 31st total of 729,300 shares. Based on an average daily trading volume, of 520,900 shares, the days-to-cover ratio is currently 0.9 days. Approximately 2.3% of the shares of the stock are short sold. View ReShape Lifesciences' Short Interest. When is ReShape Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RSLS earnings forecast. How were ReShape Lifesciences' earnings last quarter? ReShape Lifesciences Inc. (NASDAQ:RSLS) released its quarterly earnings data on Thursday, August, 13th. The medical device company reported ($8.67) EPS for the quarter, topping the consensus estimate of ($218,400.00) by $218,391.33. The medical device company earned $1.70 million during the quarter. ReShape Lifesciences had a negative net margin of 131.22% and a negative trailing twelve-month return on equity of 187.89%. When did ReShape Lifesciences' stock split? ReShape Lifesciences shares reverse split on the morning of Thursday, December 22nd 2022. The 1-50 reverse split was announced on Thursday, December 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of ReShape Lifesciences? Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RSLS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
